Viemed Healthcare’s 2026 Q2 Earnings Call: Ventilator Growth Drivers and Margin Stability Levers Clash in Contradictory Statements

Date of Call: Aug 4, 2026

Financials Results

• Revenue: $78.1M, up 24% YOY and 4% sequentially
• EPS: $0.07 per diluted share
• Gross Margin: 57.7%, compared to 58.3% in the prior year quarter and improved from 56.8% in Q1

Guidance:

• Full-year revenue expected to be $314M to $320M (raised low end from previous $312M range).
• Full-year adjusted EBITDA expected to be $64M to $68M (revised down from previous $65M to $69M range).
• Net CapEx expected to be 8.5% to 10% of revenue (lowered from previous 9% to 10.5% range).
• Expect full-year adjusted EBITDA margin of at least 20%.

Business Commentary:

Record Revenue and Diverse Growth:

• ViMed Healthcare reported record quarterly revenue of $78.1 million, increasing 24% from the prior year and 4% from the first quarter.
• Growth was driven by an increase in ventilator rental revenue, expansion in PAP setups, and strong performance in sleep therapy and maternal health businesses.

Ventilation Patient Growth and Compliance:

• The company added 546 ventilator patients during the quarter, ending with 12,635 active patients, marking a 4.5% sequential growth.
• Growth was attributed to effective adaptation to new CMS National Coverage Determination, improved compliance initiatives, and enhanced sales organization.

Expansion in Sleep and Maternal Health:

• Sleep therapy patients increased 5% sequentially and 44% year-over-year, while maternal health achieved a new quarterly high for breast pump deliveries.
• The expansion in these areas was driven by leveraging existing payer relationships and operational infrastructure, as well as strategic focus on scaling these services.

Financial Performance and Guidance:

• Adjusted EBITDA was reported at $13.7 million, with a margin of 17.6%, reflecting an increase from the prior year when adjusted for non-recurring gains.
• The company raised its full-year revenue guidance to $314 million to $320 million and expects to maintain an adjusted EBITDA margin of at least 20%.

Operational Enhancements and Efficiency:

• The integration of new technology and workflow systems reduced order processing times, enhancing operational efficiency without a proportional increase in fulfillment infrastructure.
• These improvements are expected to support future growth and scalability, allowing the company to handle increased volumes effectively.

Sentiment Analysis:

Overall Tone: Positive

• Management stated: 'We are raising the low end of our net revenue guidance... We feel very good about where the business is headed. ViMed has a strong financial foundation, a broader platform, and a team that has demonstrated it can execute. We are proud of the growth our team is producing and confident in our ability to build on it.'

Q&A:

• Question from Dave Storms (StoneGate): What are you seeing in terms of getting people in the door, their time to ramp? Anything about the sales organization revamp?
  Response: The sales reorganization added a fourth division to enable geographic expansion and a corporate ladder for growth. It focuses on training new reps faster and improving patient retention through compliance efforts, contributing to organic growth.

• Question from Dave Storms (StoneGate): How much of the strong patient growth can be attributed to the sales revamp, and is more organic growth expected?
  Response: Growth is entirely organic for complex respiratory and sleep. The revamp helps by accelerating new rep training and improving patient retention via compliance initiatives, with further improvements planned.

• Question from Dave Storms (StoneGate): Regarding guidance adjustments, is growth in sales/service revenue (resupply vs. maternal) driving the change?
  Response: Both maternal and sleep/resupply are expected to grow significantly. Maternal likely grows at a higher percentage, but both benefit from improved scalability and operational investments.

• Question from Ilya Zubkov (Freedom Brokers): Was the ventilator patient count increase partially related to insurers approving previously denied patients post-NCD changes?
  Response: Multiple factors contributed, with new orders being the largest piece, followed by improved onboarding due to formulary rules, a new sales structure, compliance efforts, and fewer insurance holds post-season.

• Question from Ilya Zubkov (Freedom Brokers): Did the revised NCD requirements change the effective capacity of the respiratory therapist workforce?
  Response: It's too early to determine a meaningful change in patient per RT ratio. The focus is on patient education and compliance, with potential for additional RTs if needed, but current heavy-count RTs are also top compliance performers.

• Question from Ilya Zubkov (Freedom Brokers): What operating leverage is expected in the second half to move EBITDA margin toward the guided 20% level?
  Response: Second half margins should align with the 23% carry from last year. Diversification into lower-margin but capital-light businesses is structurally acceptable as net income margins expand. Specific levers include new distribution partnerships, scalable intake workflows, and an in-house call center, with some cost duplication easing.

Contradiction Point 1

Primary Driver of Ventilator Patient Growth

Contradiction on whether new patient orders or system-wide factors were the main growth driver.

Ilya Zubkov (Freedom Brokers) - Ilya Zubkov (Freedom Brokers)

2026Q2: The growth was driven by several factors: new orders, formulary rules allowing more onboarding, the new sales structure, improved compliance, and fewer patients on billing holds... - Todd (CFO)

Was the increase in ventilator patient count partially due to insurers approving previously denied patients after NCD changes? - Ilya Zubkov (Freedom Brokers)

2026Q2: Several factors contributed: 1) New patient orders were the largest driver. 2) Formulary rules from the NCD helped onboard more patients... 3) The new sales structure and improved compliance efforts... - Casey Hoyt (CEO)

Contradiction Point 2

RT Workforce Capacity and Patient-to-RT Ratio

Contradiction on the timing and certainty of changes to the effective capacity of the RT workforce.

Ilya Zubkov (Freedom Brokers) - Ilya Zubkov (Freedom Brokers)

2026Q2: It is too early to determine a meaningful change in patients per RT. The company is focused on patient education and compliance. - Todd (CFO)

Have the revised NCD requirements impacted the effective capacity of the RT workforce? - Ilya Zubkov (Freedom Brokers)

2026Q2: Top-performing RTs (often with higher patient counts) are being used as compliance 'champions' to mentor others. - Casey Hoyt (CEO)

Contradiction Point 3

Attribution of Strong Patient Growth

Inconsistent attribution of growth to sales revamp versus other factors.

Dave Storms (StoneGate) - Dave Storms (StoneGate)

2026Q2: The growth in complex respiratory and sleep therapy is entirely organic. It is driven by finding and training new reps more effectively... - Casey Hoyt(CEO)

What portion of the strong patient growth is due to the sales revamp, and is further growth anticipated as it takes effect? - Dave Storms (Stonegate)

2026Q1: Ventilator new patient starts are exceeding expectations, and improving compliance metrics are key to retention and length of stay. - Casey Hoyt(CEO)

Contradiction Point 4

Growth Drivers for Maternal Health vs. Other Segments

Contradiction on whether maternal health or sleep/resupply is the primary growth driver.

Dave Storms (StoneGate) - Dave Storms (StoneGate)

2026Q2: Maternal health is expected to grow at a faster percentage than sleep/resupply, but both are expected to grow significantly. - Todd(CFO)

Given that guidance adjustments are driven by growth in sales and service revenue, which is expected to have more outsized growth: resupply or maternal health? - Dave Storms (Stonegate)

2026Q1: Maternal health is growing dramatically as the company scales its operations and expands into new markets. The sleep business continues to outperform previous expectations significantly. - Casey Hoyt(CEO)

Contradiction Point 5

Margin Stability Levers

Contradiction on the strategy for maintaining gross margin stability amid business mix changes.

Ilya Zubkov (Freedom Brokers) - Ilya Zubkov (Freedom Brokers)

2026Q2: Diversification into lower-margin but low-capex businesses like sleep/resupply and maternal health will expand net income margins. - Todd(CFO)

What operating leverage is expected in the second half to move the EBITDA margin toward the guided 20% level? - David Storms (Stonegate Capital Partners, Inc., Research Division)

2025Q4: Gross margins are expected to be kept relatively flat, which is an ongoing challenge as higher-margin products like ventilator rentals carry higher costs. - Todd Zehnder(CFO)